Pulse Biosciences (PLSE) Equity Average (2016 - 2025)

Pulse Biosciences has reported Equity Average for 10 years, with the latest figure at $86.7 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 10.64% year-over-year to $86.7 million; the trailing twelve-month figure through Dec 2025 stood at $86.7 million (down 10.64% YoY), and the FY2025 full-year result was $97.8 million, up 22.8% from the prior year.
• Equity Average for Q4 2025 stood at $86.7 million, down from $98.6 million in the prior quarter.
• The five-year high for Equity Average was $116.7 million in Q1 2025, with the low at -$6.5 million in Q1 2023.
• Average Equity Average over 5 years is $49.6 million, with a median of $43.1 million recorded in 2021.
• Peak annual rise in Equity Average reached 2348.74% in 2023, while the deepest fall reached 119.82% in 2023.
• Tracing PLSE's Equity Average over 5 years: stood at $45.9 million in 2021, then slumped by 95.7% to $2.0 million in 2022, then soared by 2348.74% to $48.3 million in 2023, then surged by 101.02% to $97.0 million in 2024, then dropped by 10.64% to $86.7 million in 2025.
• The last three Equity Average figures came in at $86.7 million (Q4 2025), $98.6 million (Q3 2025), and $111.5 million (Q2 2025), per Business Quant data.

Peer Comparison